aluates Reports

$ 0.0

Automative

Global DTaP and Tdap Vaccines Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-2L9079

Global DTaP and Tdap Vaccines Market Insights and Forecast to 2028

BUY CHAPTERS

Global DTaP and Tdap Vaccines Market Research Report 2025

Code: QYRE-Auto-2L9079

Report

September 2025

Pages:96

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi Pasteur

GlaxoSmithKline PLC

Protein Sciences Corporation

Novartis

Seqirus

Merck Sharp& Dohme Corp

Astellas pharma US Inc.

Pfizer Inc

Johnson & Johnson

Lanzhou Institute of Biological Products Co., Ltd

Astrazeneca plc

Emergent BioSolutions Inc

Merck Sharp& Dohme Corp

Johnson & Johnson

DTaP and Tdap Vaccines Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

DTaP and Tdap Vaccines Market

The global market for DTaP and Tdap Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines.

The DTaP and Tdap Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global DTaP and Tdap Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the DTaP and Tdap Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of DTaP and Tdap Vaccines Market Report

Report Metric	Details
Report Name	DTaP and Tdap Vaccines Market
CAGR	5%
Segment by Type	DTaP Td Tdap
Segment by Application	Adult Pediatric
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc, Johnson & Johnson, Lanzhou Institute of Biological Products Co., Ltd, AstraZeneca, Emergent BioSolutions Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the DTaP and Tdap Vaccines Market report?

Ans: The main players in the DTaP and Tdap Vaccines Market are Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc, Johnson & Johnson, Lanzhou Institute of Biological Products Co., Ltd, AstraZeneca, Emergent BioSolutions Inc

What are the Application segmentation covered in the DTaP and Tdap Vaccines Market report?

Ans: The Applications covered in the DTaP and Tdap Vaccines Market report are Adult, Pediatric

What are the Type segmentation covered in the DTaP and Tdap Vaccines Market report?

Ans: The Types covered in the DTaP and Tdap Vaccines Market report are DTaP, Td, Tdap

Recommended Reports

Pediatric and Combo Vaccines

Disease Specific Vaccines

Vaccine Technologies

1 DTaP and Tdap Vaccines Market Overview

1.1 Product Definition

1.2 DTaP and Tdap Vaccines by Type

1.2.1 Global DTaP and Tdap Vaccines Market Value Comparison by Type (2024 VS 2031)

1.2.2 DTaP

1.2.3 Td

1.2.4 Tdap

1.3 DTaP and Tdap Vaccines by Application

1.3.1 Global DTaP and Tdap Vaccines Market Value by Application (2024 VS 2031)

1.3.2 Adult

1.3.3 Pediatric

1.4 Global DTaP and Tdap Vaccines Market Size Estimates and Forecasts

1.4.1 Global DTaP and Tdap Vaccines Revenue 2020-2031

1.4.2 Global DTaP and Tdap Vaccines Sales 2020-2031

1.4.3 Global DTaP and Tdap Vaccines Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 DTaP and Tdap Vaccines Market Competition by Manufacturers

2.1 Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers (2020-2025)

2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Manufacturers (2020-2025)

2.3 Global DTaP and Tdap Vaccines Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of DTaP and Tdap Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of DTaP and Tdap Vaccines, Product Type & Application

2.7 Global Key Manufacturers of DTaP and Tdap Vaccines, Date of Enter into This Industry

2.8 Global DTaP and Tdap Vaccines Market Competitive Situation and Trends

2.8.1 Global DTaP and Tdap Vaccines Market Concentration Rate

2.8.2 The Global 5 and 10 Largest DTaP and Tdap Vaccines Players Market Share by Revenue

2.8.3 Global DTaP and Tdap Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global DTaP and Tdap Vaccines Market Scenario by Region

3.1 Global DTaP and Tdap Vaccines Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global DTaP and Tdap Vaccines Sales by Region: 2020-2031

3.2.1 Global DTaP and Tdap Vaccines Sales by Region: 2020-2025

3.2.2 Global DTaP and Tdap Vaccines Sales by Region: 2026-2031

3.3 Global DTaP and Tdap Vaccines Revenue by Region: 2020-2031

3.3.1 Global DTaP and Tdap Vaccines Revenue by Region: 2020-2025

3.3.2 Global DTaP and Tdap Vaccines Revenue by Region: 2026-2031

3.4 North America DTaP and Tdap Vaccines Market Facts & Figures by Country

3.4.1 North America DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America DTaP and Tdap Vaccines Sales by Country (2020-2031)

3.4.3 North America DTaP and Tdap Vaccines Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe DTaP and Tdap Vaccines Market Facts & Figures by Country

3.5.1 Europe DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe DTaP and Tdap Vaccines Sales by Country (2020-2031)

3.5.3 Europe DTaP and Tdap Vaccines Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific DTaP and Tdap Vaccines Market Facts & Figures by Region

3.6.1 Asia Pacific DTaP and Tdap Vaccines Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific DTaP and Tdap Vaccines Sales by Region (2020-2031)

3.6.3 Asia Pacific DTaP and Tdap Vaccines Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America DTaP and Tdap Vaccines Market Facts & Figures by Country

3.7.1 Latin America DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America DTaP and Tdap Vaccines Sales by Country (2020-2031)

3.7.3 Latin America DTaP and Tdap Vaccines Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa DTaP and Tdap Vaccines Market Facts & Figures by Country

3.8.1 Middle East and Africa DTaP and Tdap Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2020-2031)

3.8.3 Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global DTaP and Tdap Vaccines Sales by Type (2020-2031)

4.1.1 Global DTaP and Tdap Vaccines Sales by Type (2020-2025)

4.1.2 Global DTaP and Tdap Vaccines Sales by Type (2026-2031)

4.1.3 Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2031)

4.2 Global DTaP and Tdap Vaccines Revenue by Type (2020-2031)

4.2.1 Global DTaP and Tdap Vaccines Revenue by Type (2020-2025)

4.2.2 Global DTaP and Tdap Vaccines Revenue by Type (2026-2031)

4.2.3 Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2031)

4.3 Global DTaP and Tdap Vaccines Price by Type (2020-2031)

5 Segment by Application

5.1 Global DTaP and Tdap Vaccines Sales by Application (2020-2031)

5.1.1 Global DTaP and Tdap Vaccines Sales by Application (2020-2025)

5.1.2 Global DTaP and Tdap Vaccines Sales by Application (2026-2031)

5.1.3 Global DTaP and Tdap Vaccines Sales Market Share by Application (2020-2031)

5.2 Global DTaP and Tdap Vaccines Revenue by Application (2020-2031)

5.2.1 Global DTaP and Tdap Vaccines Revenue by Application (2020-2025)

5.2.2 Global DTaP and Tdap Vaccines Revenue by Application (2026-2031)

5.2.3 Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2031)

5.3 Global DTaP and Tdap Vaccines Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Sanofi Pasteur

6.1.1 Sanofi Pasteur Company Information

6.1.2 Sanofi Pasteur Description and Business Overview

6.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio

6.1.5 Sanofi Pasteur Recent Developments/Updates

6.2 GlaxoSmithKline

6.2.1 GlaxoSmithKline Company Information

6.2.2 GlaxoSmithKline Description and Business Overview

6.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio

6.2.5 GlaxoSmithKline Recent Developments/Updates

6.3 Protein Sciences Corporation

6.3.1 Protein Sciences Corporation Company Information

6.3.2 Protein Sciences Corporation Description and Business Overview

6.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio

6.3.5 Protein Sciences Corporation Recent Developments/Updates

6.4 Novartis AG

6.4.1 Novartis AG Company Information

6.4.2 Novartis AG Description and Business Overview

6.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio

6.4.5 Novartis AG Recent Developments/Updates

6.5 Seqirus

6.5.1 Seqirus Company Information

6.5.2 Seqirus Description and Business Overview

6.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Seqirus DTaP and Tdap Vaccines Product Portfolio

6.5.5 Seqirus Recent Developments/Updates

6.6 Merck Sharp & Dohme Corp

6.6.1 Merck Sharp & Dohme Corp Company Information

6.6.2 Merck Sharp & Dohme Corp Description and Business Overview

6.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio

6.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates

6.7 Astellas Pharma US, Inc

6.7.1 Astellas Pharma US, Inc Company Information

6.7.2 Astellas Pharma US, Inc Description and Business Overview

6.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio

6.7.5 Astellas Pharma US, Inc Recent Developments/Updates

6.8 Pfizer Inc

6.8.1 Pfizer Inc Company Information

6.8.2 Pfizer Inc Description and Business Overview

6.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio

6.8.5 Pfizer Inc Recent Developments/Updates

6.9 Johnson & Johnson

6.9.1 Johnson & Johnson Company Information

6.9.2 Johnson & Johnson Description and Business Overview

6.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio

6.9.5 Johnson & Johnson Recent Developments/Updates

6.10 Lanzhou Institute of Biological Products Co., Ltd

6.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information

6.10.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview

6.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio

6.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates

6.11 AstraZeneca

6.11.1 AstraZeneca Company Information

6.11.2 AstraZeneca Description and Business Overview

6.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.11.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio

6.11.5 AstraZeneca Recent Developments/Updates

6.12 Emergent BioSolutions Inc

6.12.1 Emergent BioSolutions Inc Company Information

6.12.2 Emergent BioSolutions Inc Description and Business Overview

6.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio

6.12.5 Emergent BioSolutions Inc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 DTaP and Tdap Vaccines Industry Chain Analysis

7.2 DTaP and Tdap Vaccines Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 DTaP and Tdap Vaccines Production Mode & Process Analysis

7.4 DTaP and Tdap Vaccines Sales and Marketing

7.4.1 DTaP and Tdap Vaccines Sales Channels

7.4.2 DTaP and Tdap Vaccines Distributors

7.5 DTaP and Tdap Vaccines Customer Analysis

8 DTaP and Tdap Vaccines Market Dynamics

8.1 DTaP and Tdap Vaccines Industry Trends

8.2 DTaP and Tdap Vaccines Market Drivers

8.3 DTaP and Tdap Vaccines Market Challenges

8.4 DTaP and Tdap Vaccines Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi Pasteur

GlaxoSmithKline PLC

Protein Sciences Corporation

Novartis

Seqirus

Merck Sharp& Dohme Corp

Astellas pharma US Inc.

Pfizer Inc

Johnson & Johnson

Lanzhou Institute of Biological Products Co., Ltd

Astrazeneca plc

Emergent BioSolutions Inc

Merck Sharp& Dohme Corp

Johnson & Johnson

List of Tables

Table 1. Global DTaP and Tdap Vaccines Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global DTaP and Tdap Vaccines Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global DTaP and Tdap Vaccines Market Competitive Situation by Manufacturers in 2024

Table 4. Global DTaP and Tdap Vaccines Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers (2020-2025)

Table 6. Global DTaP and Tdap Vaccines Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global DTaP and Tdap Vaccines Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market DTaP and Tdap Vaccines Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of DTaP and Tdap Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of DTaP and Tdap Vaccines, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of DTaP and Tdap Vaccines, Product Type & Application

Table 12. Global Key Manufacturers of DTaP and Tdap Vaccines, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global DTaP and Tdap Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DTaP and Tdap Vaccines as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global DTaP and Tdap Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global DTaP and Tdap Vaccines Sales by Region (2020-2025) & (K Units)

Table 18. Global DTaP and Tdap Vaccines Sales Market Share by Region (2020-2025)

Table 19. Global DTaP and Tdap Vaccines Sales by Region (2026-2031) & (K Units)

Table 20. Global DTaP and Tdap Vaccines Sales Market Share by Region (2026-2031)

Table 21. Global DTaP and Tdap Vaccines Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2020-2025)

Table 23. Global DTaP and Tdap Vaccines Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2026-2031)

Table 25. North America DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)

Table 27. North America DTaP and Tdap Vaccines Sales by Country (2026-2031) & (K Units)

Table 28. North America DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)

Table 32. Europe DTaP and Tdap Vaccines Sales by Country (2026-2031) & (K Units)

Table 33. Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific DTaP and Tdap Vaccines Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific DTaP and Tdap Vaccines Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific DTaP and Tdap Vaccines Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific DTaP and Tdap Vaccines Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific DTaP and Tdap Vaccines Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)

Table 42. Latin America DTaP and Tdap Vaccines Sales by Country (2026-2031) & (K Units)

Table 43. Latin America DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa DTaP and Tdap Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global DTaP and Tdap Vaccines Sales (K Units) by Type (2020-2025)

Table 51. Global DTaP and Tdap Vaccines Sales (K Units) by Type (2026-2031)

Table 52. Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)

Table 53. Global DTaP and Tdap Vaccines Sales Market Share by Type (2026-2031)

Table 54. Global DTaP and Tdap Vaccines Revenue (US$ Million) by Type (2020-2025)

Table 55. Global DTaP and Tdap Vaccines Revenue (US$ Million) by Type (2026-2031)

Table 56. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)

Table 57. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2026-2031)

Table 58. Global DTaP and Tdap Vaccines Price (USD/Unit) by Type (2020-2025)

Table 59. Global DTaP and Tdap Vaccines Price (USD/Unit) by Type (2026-2031)

Table 60. Global DTaP and Tdap Vaccines Sales (K Units) by Application (2020-2025)

Table 61. Global DTaP and Tdap Vaccines Sales (K Units) by Application (2026-2031)

Table 62. Global DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)

Table 63. Global DTaP and Tdap Vaccines Sales Market Share by Application (2026-2031)

Table 64. Global DTaP and Tdap Vaccines Revenue (US$ Million) by Application (2020-2025)

Table 65. Global DTaP and Tdap Vaccines Revenue (US$ Million) by Application (2026-2031)

Table 66. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2025)

Table 67. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2026-2031)

Table 68. Global DTaP and Tdap Vaccines Price (USD/Unit) by Application (2020-2025)

Table 69. Global DTaP and Tdap Vaccines Price (USD/Unit) by Application (2026-2031)

Table 70. Sanofi Pasteur Company Information

Table 71. Sanofi Pasteur Description and Business Overview

Table 72. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Sanofi Pasteur DTaP and Tdap Vaccines Product

Table 74. Sanofi Pasteur Recent Developments/Updates

Table 75. GlaxoSmithKline Company Information

Table 76. GlaxoSmithKline Description and Business Overview

Table 77. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. GlaxoSmithKline DTaP and Tdap Vaccines Product

Table 79. GlaxoSmithKline Recent Developments/Updates

Table 80. Protein Sciences Corporation Company Information

Table 81. Protein Sciences Corporation Description and Business Overview

Table 82. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Protein Sciences Corporation DTaP and Tdap Vaccines Product

Table 84. Protein Sciences Corporation Recent Developments/Updates

Table 85. Novartis AG Company Information

Table 86. Novartis AG Description and Business Overview

Table 87. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Novartis AG DTaP and Tdap Vaccines Product

Table 89. Novartis AG Recent Developments/Updates

Table 90. Seqirus Company Information

Table 91. Seqirus Description and Business Overview

Table 92. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Seqirus DTaP and Tdap Vaccines Product

Table 94. Seqirus Recent Developments/Updates

Table 95. Merck Sharp & Dohme Corp Company Information

Table 96. Merck Sharp & Dohme Corp Description and Business Overview

Table 97. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product

Table 99. Merck Sharp & Dohme Corp Recent Developments/Updates

Table 100. Astellas Pharma US, Inc Company Information

Table 101. Astellas Pharma US, Inc Description and Business Overview

Table 102. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product

Table 104. Astellas Pharma US, Inc Recent Developments/Updates

Table 105. Pfizer Inc Company Information

Table 106. Pfizer Inc Description and Business Overview

Table 107. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Pfizer Inc DTaP and Tdap Vaccines Product

Table 109. Pfizer Inc Recent Developments/Updates

Table 110. Johnson & Johnson Company Information

Table 111. Johnson & Johnson Description and Business Overview

Table 112. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Johnson & Johnson DTaP and Tdap Vaccines Product

Table 114. Johnson & Johnson Recent Developments/Updates

Table 115. Lanzhou Institute of Biological Products Co., Ltd Company Information

Table 116. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview

Table 117. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product

Table 119. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates

Table 120. AstraZeneca Company Information

Table 121. AstraZeneca Description and Business Overview

Table 122. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. AstraZeneca DTaP and Tdap Vaccines Product

Table 124. AstraZeneca Recent Developments/Updates

Table 125. Emergent BioSolutions Inc Company Information

Table 126. Emergent BioSolutions Inc Description and Business Overview

Table 127. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 128. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product

Table 129. Emergent BioSolutions Inc Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. DTaP and Tdap Vaccines Distributors List

Table 133. DTaP and Tdap Vaccines Customers List

Table 134. DTaP and Tdap Vaccines Market Trends

Table 135. DTaP and Tdap Vaccines Market Drivers

Table 136. DTaP and Tdap Vaccines Market Challenges

Table 137. DTaP and Tdap Vaccines Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of DTaP and Tdap Vaccines

Figure 2. Global DTaP and Tdap Vaccines Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global DTaP and Tdap Vaccines Market Share by Type: 2024 & 2031

Figure 4. DTaP Product Picture

Figure 5. Td Product Picture

Figure 6. Tdap Product Picture

Figure 7. Global DTaP and Tdap Vaccines Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global DTaP and Tdap Vaccines Market Share by Application: 2024 & 2031

Figure 9. Adult

Figure 10. Pediatric

Figure 11. Global DTaP and Tdap Vaccines Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global DTaP and Tdap Vaccines Market Size (2020-2031) & (US$ Million)

Figure 13. Global DTaP and Tdap Vaccines Sales (2020-2031) & (K Units)

Figure 14. Global DTaP and Tdap Vaccines Average Price (USD/Unit) & (2020-2031)

Figure 15. DTaP and Tdap Vaccines Report Years Considered

Figure 16. DTaP and Tdap Vaccines Sales Share by Manufacturers in 2024

Figure 17. Global DTaP and Tdap Vaccines Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest DTaP and Tdap Vaccines Players: Market Share by Revenue in DTaP and Tdap Vaccines in 2024

Figure 19. DTaP and Tdap Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global DTaP and Tdap Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)

Figure 22. North America DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)

Figure 23. U.S. DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)

Figure 26. Europe DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)

Figure 27. Germany DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific DTaP and Tdap Vaccines Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific DTaP and Tdap Vaccines Revenue Market Share by Region (2020-2031)

Figure 34. China DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Taiwan DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Philippines DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)

Figure 45. Latin America DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)

Figure 46. Mexico DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa DTaP and Tdap Vaccines Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2031)

Figure 51. Turkey DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE DTaP and Tdap Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of DTaP and Tdap Vaccines by Type (2020-2031)

Figure 55. Global Revenue Market Share of DTaP and Tdap Vaccines by Type (2020-2031)

Figure 56. Global DTaP and Tdap Vaccines Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of DTaP and Tdap Vaccines by Application (2020-2031)

Figure 58. Global Revenue Market Share of DTaP and Tdap Vaccines by Application (2020-2031)

Figure 59. Global DTaP and Tdap Vaccines Price (USD/Unit) by Application (2020-2031)

Figure 60. DTaP and Tdap Vaccines Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Diphtheria Tetanus Pertussis Vaccine Market Research Report 2025

Global Pertussis Vaccine Market Insights Forecast to 2030

Diphtheria Tetanus Pertussis Mix Vaccine for Children Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pertussis Vaccination Market Research Report 2025

Global TD Vaccine Market Research Report 2025

DTaP Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Diphtheria Tetanus and Acellular Pertussis Combined Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Maternal Pertussis Vaccine for Newborn Protection Market Research Report 2024

Global Pertussis Treatment Market Research Report 2024

Global Tetanus Vaccine Market Insights Forecast to 2030

Global DPT Vaccines Market Research Report 2025

Global DPT Vaccination Market Research Report 2025

Global Component DTP Vaccine Market Research Report 2024

Global DT Based Combined Vaccines Market Research Report 2024

Global Tetanus Toxoid Vaccine Market Research Report 2024

Global Vaccines For Children Market Insights Forecast to 2030

Global Whooping Cough Preventable Vaccine Market Research Report 2024

Global Pertussis Booster Vaccine Market Research Report 2024

Global Diphtheria Vaccines Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions